scholarly journals Correction: Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa

PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
Author(s):  
Karen Shean ◽  
Elizabeth Streicher ◽  
Elize Pieterson ◽  
Greg Symons ◽  
Richard van Zyl Smit ◽  
...  
Keyword(s):  
South Africa ◽  
Adverse Events ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Extensively Drug Resistant

scholarly journals Drug-Associated Adverse Events and Their Relationship with Outcomes in Patients Receiving Treatment for Extensively Drug-Resistant Tuberculosis in South Africa

PLoS ONE ◽  
2013 ◽  
Vol 8 (5) ◽  
pp. e63057 ◽  
Author(s):  
Karen Shean ◽  
Elizabeth Streicher ◽  
Elize Pieterson ◽  
Greg Symons ◽  
Richard van Zyl Smit ◽  
...  
Keyword(s):  
South Africa ◽  
Adverse Events ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Extensively Drug Resistant

scholarly journals Genome Analysis of Multi- and Extensively-Drug-Resistant Tuberculosis from KwaZulu-Natal, South Africa

PLoS ONE ◽  
2009 ◽  
Vol 4 (11) ◽  
pp. e7778 ◽  
Author(s):  
Thomas R. Ioerger ◽  
Sunwoo Koo ◽  
Eun-Gyu No ◽  
Xiaohua Chen ◽  
Michelle H. Larsen ◽  
...  
Keyword(s):  
South Africa ◽  
Genome Analysis ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Extensively Drug Resistant ◽  
Kwazulu Natal

Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study

The Lancet ◽  
2014 ◽  
Vol 383 (9924) ◽  
pp. 1230-1239 ◽  
Author(s):  
Elize Pietersen ◽  
Elisa Ignatius ◽  
Elizabeth M Streicher ◽  
Barbara Mastrapa ◽  
Xavier Padanilam ◽  
...  
Keyword(s):  
South Africa ◽  
Cohort Study ◽  
Drug Resistant ◽  
Long Term Outcomes ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Extensively Drug Resistant

scholarly journals Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China

2014 ◽  
Vol 45 (1) ◽  
pp. 161-170 ◽  
Author(s):  
Shenjie Tang ◽  
Lan Yao ◽  
Xiaohui Hao ◽  
Xia Zhang ◽  
Gang Liu ◽  
...  
Keyword(s):  
Adverse Events ◽  
Success Rate ◽  
Therapy Group ◽  
Treatment Success ◽  
Control Group ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Extensively Drug Resistant ◽  
Linezolid Therapy

Linezolid may be effective in treating multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. We conducted a prospective, multicentre, randomised study to further evaluate the efficacy, safety and tolerability of linezolid in patients with extensively drug-resistant tuberculosis in China.65 patients who had culture-positive sputum for extensively drug-resistant tuberculosis were randomly assigned to a linezolid therapy group or a control group. Patients in the two groups adopted a 2-year individually based chemotherapy regimen. The linezolid therapy group was given linezolid at a start dose of 1200 mg per day for a period of 4–6 weeks and this was then followed by a dose of 300–600 mg per day.The proportion of sputum culture conversions in the linezolid therapy group was 78.8% by 24 months, significantly higher than that in the control group (37.6%, p<0.001). The treatment success rate in linezolid therapy group was 69.7%, significantly higher than that in the control group (34.4%, p=0.004). 27 (81.8%) patients had clinically significant adverse events in the linezolid group, of whom 25 (93%) patients had events that were possibly or probably related to linezolid. Most adverse events resolved after reducing the dosage of linezolid or temporarily discontinuing linezolid.Linezolid containing chemotherapy for treatment of extensively drug-resistant tuberculosis may significantly promote cavity closure, increase sputum culture-conversion rate and improve treatment success rate.

scholarly journals Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines

BMJ Open ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. e051521
Author(s):  
Gabriela Beatriz Gomez ◽  
Mariana Siapka ◽  
Francesca Conradie ◽  
Norbert Ndjeka ◽  
Anna Marie Celina Garfin ◽  
...  
Keyword(s):  
South Africa ◽  
Cost Effectiveness ◽  
Standard Of Care ◽  
The Philippines ◽  
List Price ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Extensively Drug Resistant ◽  
Mdr Tb

ObjectivesPatients with highly resistant tuberculosis have few treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present an economic evaluation of introducing BPaL against the extensively drug-resistant tuberculosis (XDR-TB) standard of care in three epidemiological settings.DesignCost-effectiveness analysis using Markov cohort model.SettingSouth Africa, Georgia and the Philippines.ParticipantsXDR-TB and multidrug-resistant tuberculosis (MDR-TB) failure and treatment intolerant patients.InterventionsBPaL regimen.Primary and secondary outcome measures(1) Incremental cost per disability-adjusted life years averted by using BPaL against standard of care at the Global Drug Facility list price. (2) The potential maximum price at which the BPaL regimen could become cost neutral.ResultsBPaL for XDR-TB is likely to be cost saving in all study settings when pretomanid is priced at the Global Drug Facility list price. The magnitude of these savings depends on the prevalence of XDR-TB in the country and can amount, over 5 years, to approximately US$ 3 million in South Africa, US$ 200 000 and US$ 60 000 in Georgia and the Philippines, respectively. In South Africa, related future costs of antiretroviral treatment (ART) due to survival of more patients following treatment with BPaL reduced the magnitude of expected savings to approximately US$ 1 million. Overall, when BPaL is introduced to a wider population, including MDR-TB treatment failure and treatment intolerant, we observe increased savings and clinical benefits. The potential threshold price at which the probability of the introduction of BPaL becoming cost neutral begins to increase is higher in Georgia and the Philippines (US$ 3650 and US$ 3800, respectively) compared with South Africa (US$ 500) including ART costs.ConclusionsOur results estimate that BPaL can be a cost-saving addition to the local TB programmes in varied programmatic settings.

Sign in / Sign up

Export Citation Format

Share Document